Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that, on Thursday, March 28, 2019, at approximately 8:00 a.m. ET, it will issue a press release announcing the results of its final Phase III study for SPN-812 in patients 12-17 years old (P304) for the treatment of attention deficit hyperactivity disorder (ADHD).
Supernus will hold a conference call and webcast on Thursday, March 28, 2019, at 9:00 a.m. ET to discuss the topline results of the clinical trial. Presentation slides will be made available approximately 30 minutes prior to the call. The call will be hosted by Jack Khattar, President and Chief Executive Officer; Stefan Schwabe, Chief Medical Officer and Executive Vice President of Research & Development; and Greg Patrick, Senior Vice President and Chief Financial Officer.
Conference Call Details
Presentation slides will be available via this webcast link approximately 30 minutes prior to the conference and webcast. A question and answer session with the Supernus management team will follow the Company’s remarks.
Please refer to the information below for conference call dial-in information and webcast registration. Callers should dial in approximately 10 minutes prior to the start of the call.
| Conference dial-in: | (877) 288-1043 | |
| International dial-in: | (970) 315-0267 | |
| Conference ID: | 9278115 | |
| Conference Call Name: | Supernus Pharmaceuticals SPN-812 Phase III Topline Results | |
| Webcast link: | Click here | |
Following the live call, a replay will be available on the company’s website, http://www.supernus.com, under ‘Investors Relations’.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.